Boobalan Pachaiyappan Analyst Performance

Boobalan Pachaiyappan, Ph.D., is a Managing Director and Senior Biotech Analyst at Roth Capital Partners, with ~13 years of post-Ph.D. work experience in biomedical sciences, including five years of equity research experience as a sell­side Analyst. At Roth, he is responsible for fortifying the firm's SMID-cap coverage of emerging growth companies in the Healthcare sector, with a predilection towards neurology, neuropsychiatry, neuromuscular disorders and pain. Boobalan embarked on his Equity Research career as an Associate at H.C. Wainwright and quickly advanced to Vice President and Director roles. At H.C. Wainwright, he contributed significantly to 40 initiation reports, holding primary/co-primary responsibility for 20 stocks. Boobalan was awarded a Ph.D. in Medicinal Chemistry (University of Illinois at Chicago) and an M.S. in Chemistry (Virginia Tech). His scientific work has been featured in 14 peer-reviewed scientific journals and/or industry magazines, and he was a co-inventor of a World Patent. During his academic research career, he received several awards, including the Robert M. Scarborough Award for Excellence in Medicinal Chemistry (American Chemical Society) and the Outstanding Young Investigator award (Alzheimer's Drug Discovery Foundation). He held multiple leadership roles, including President of the Medical University of South Carolina Postdoctoral Association and Chairman of the American Association of Pharmaceutical Scientists, University of Illinois at Chicago Chapter.